inositol has been researched along with Dementia Praecox in 33 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Inositol is a key metabolite in the phosphatidylinositol cycle, which is a second messenger system for serotonin-2 receptors that have been implicated in the pathophysiology of schizophrenia." | 9.07 | CSF inositol in schizophrenia and high-dose inositol treatment of schizophrenia. ( Agam, G; Belmaker, RH; Elizur, A; Goldberger, I; Levine, J; Rapaport, A; Schield, C; Schwartz, M; Shapiro, J, 1994) |
| "Myo-Inositol in the ACC was negatively correlated with MTSD-Trait scores in both patients (ρ=-0." | 5.42 | Evaluation of Myo-Inositol as a Potential Biomarker for Depression in Schizophrenia. ( Chiappelli, J; Gaston, F; Hong, LE; Kochunov, P; McMahon, RP; Muellerklein, F; Rowland, LM; Tagamets, M; Wijtenburg, SA, 2015) |
| "Myo-inositol is mainly found in astroglia and its levels has been shown to be reduced in the anterior cingulate cortex (ACC) of patients with schizophrenia." | 5.41 | The trajectory of putative astroglial dysfunction in first episode schizophrenia: a longitudinal 7-Tesla MRS study. ( Jeon, P; Mackinley, M; Palaniyappan, L; Théberge, J, 2021) |
| "Inositol is a key metabolite in the phosphatidylinositol cycle, which is a second messenger system for serotonin-2 receptors that have been implicated in the pathophysiology of schizophrenia." | 5.07 | CSF inositol in schizophrenia and high-dose inositol treatment of schizophrenia. ( Agam, G; Belmaker, RH; Elizur, A; Goldberger, I; Levine, J; Rapaport, A; Schield, C; Schwartz, M; Shapiro, J, 1994) |
| "Glutamate plus glutamine was positively correlated with overall cognitive performance in the schizophrenia group (p = ." | 3.77 | Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. ( Apfeldorf, W; Bustillo, JR; Caprihan, A; Chen, H; Gasparovic, C; Lauriello, J; Mullins, P; Posse, S; Qualls, C, 2011) |
| "In the anterior cingulate gyrus, patients with schizophrenia and GS showed significant decreases in N-acetyl aspartate/creatine-phosphocreatinine (NAA/Cr), choline/creatine-phosphocreatinine (Cho/Cr) and myoinositol/creatine-phosphocreatinine (ml/Cr) ratios compared with healthy subjects and compared with patients with schizophrenia without GS." | 3.73 | Proton magnetic resonance spectroscopy of the anterior cingulate gyrus, insular cortex and thalamus in schizophrenia associated with idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome). ( Horiguchi, J; Inagaki, T; Kitagaki, H; Miyaoka, T; Mizuno, S; Oda, K; Yasukawa, R, 2005) |
| "Inositol is a simple polyol precursor in a second messenger system important in the brain." | 2.68 | Controlled trials of inositol in psychiatry. ( Levine, J, 1997) |
| "Oral inositol treatment of 8 patients is shown to significantly increase CSF inositol by almost 70%, suggesting possible CNS therapeutic applications of this compound and possible CNS side-effects of systemic therapy." | 2.67 | Inositol treatment raises CSF inositol levels. ( Agam, G; Belmaker, RH; Bersudsky, Y; Kofman, O; Lev, L; Levine, J; Rapaport, A; Shapiro, J, 1993) |
| "Myo-inositol is an important part of the phosphatidylinositol second messenger system (PI-cycle)." | 2.43 | A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders--focus on magnetic resonance spectroscopy (MRS) studies. ( Kim, H; McGrath, BM; Silverstone, PH, 2005) |
| "Myo-Inositol in the ACC was negatively correlated with MTSD-Trait scores in both patients (ρ=-0." | 1.42 | Evaluation of Myo-Inositol as a Potential Biomarker for Depression in Schizophrenia. ( Chiappelli, J; Gaston, F; Hong, LE; Kochunov, P; McMahon, RP; Muellerklein, F; Rowland, LM; Tagamets, M; Wijtenburg, SA, 2015) |
| "Sixty-three first-episode treatment-naïve schizophrenia (FES) patients and 63 age-, gender- and education level-matched healthy controls were recruited." | 1.38 | Detection of metabolites in the white matter of frontal lobes and hippocampus with proton in first-episode treatment-naïve schizophrenia patients. ( Chen, ZF; Collier, DA; Deng, W; He, ZL; Li, ML; Li, T; Ma, X, 2012) |
| "Schizophrenia is associated with significant brain abnormalities, including changes in brain metabolites as measured by proton magnetic resonance spectroscopy (MRS)." | 1.35 | A 1H-MRS investigation of the medial temporal lobe in antipsychotic-naïve and early-treated first episode psychosis. ( Berger, GE; McConchie, M; McGorry, PD; Pantelis, C; Proffitt, T; Velakoulis, D; Wellard, RM; Wood, SJ, 2008) |
| "Inositol levels were assayed gas-chromatographically as trimethylsilyl derivatives with mannitol as an internal standard." | 1.30 | Inositol levels are decreased in postmortem brain of schizophrenic patients. ( Agam, G; Belmaker, RH; Davidson, M; Haroutunian, V; Shimon, H; Sobolev, Y, 1998) |
| "Schizophrenia is a disorder with an unclear pathophysiology, despite numerous attempts to elucidate its etiology." | 1.30 | Regional proton magnetic resonance spectroscopy in schizophrenia and exploration of drug effect. ( Cardwell, D; Heimberg, C; Karson, CN; Komoroski, RA; Lawson, WB, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.03) | 18.7374 |
| 1990's | 10 (30.30) | 18.2507 |
| 2000's | 7 (21.21) | 29.6817 |
| 2010's | 14 (42.42) | 24.3611 |
| 2020's | 1 (3.03) | 2.80 |
| Authors | Studies |
|---|---|
| Jeon, P | 1 |
| Mackinley, M | 1 |
| Théberge, J | 1 |
| Palaniyappan, L | 1 |
| Singh, S | 1 |
| Khushu, S | 1 |
| Kumar, P | 1 |
| Goyal, S | 1 |
| Bhatia, T | 1 |
| Deshpande, SN | 1 |
| Plitman, E | 2 |
| Chavez, S | 2 |
| Nakajima, S | 1 |
| Iwata, Y | 1 |
| Chung, JK | 1 |
| Caravaggio, F | 1 |
| Kim, J | 1 |
| Alshehri, Y | 1 |
| Chakravarty, MM | 1 |
| De Luca, V | 1 |
| Remington, G | 1 |
| Gerretsen, P | 1 |
| Graff-Guerrero, A | 2 |
| Sekar, S | 1 |
| Grandjean, J | 1 |
| Garnell, JF | 1 |
| Willems, R | 1 |
| Duytschaever, H | 1 |
| Seramani, S | 1 |
| Su, H | 1 |
| Ver Donck, L | 1 |
| Bhakoo, KK | 1 |
| Chiappelli, J | 2 |
| Rowland, LM | 2 |
| Wijtenburg, SA | 2 |
| Muellerklein, F | 1 |
| Tagamets, M | 1 |
| McMahon, RP | 1 |
| Gaston, F | 2 |
| Kochunov, P | 2 |
| Hong, LE | 2 |
| Mazgaj, R | 1 |
| Tal, A | 1 |
| Goetz, R | 1 |
| Lazar, M | 1 |
| Rothman, K | 1 |
| Messinger, JW | 1 |
| Malaspina, D | 1 |
| Gonen, O | 1 |
| Du, X | 1 |
| Strzelecki, D | 1 |
| Podgórski, M | 1 |
| Kałużyńska, O | 1 |
| Gawlik-Kotelnicka, O | 1 |
| Stefańczyk, L | 1 |
| Kotlicka-Antczak, M | 1 |
| Gmitrowicz, A | 1 |
| Grzelak, P | 1 |
| de la Fuente-Sandoval, C | 1 |
| Reyes-Madrigal, F | 1 |
| Gómez-Cruz, G | 1 |
| León-Ortiz, P | 1 |
| Brandt, AS | 1 |
| Unschuld, PG | 1 |
| Pradhan, S | 1 |
| Lim, IA | 1 |
| Churchill, G | 1 |
| Harris, AD | 1 |
| Hua, J | 1 |
| Barker, PB | 1 |
| Ross, CA | 1 |
| van Zijl, PC | 1 |
| Edden, RA | 1 |
| Margolis, RL | 1 |
| Lutkenhoff, ES | 1 |
| van Erp, TG | 1 |
| Thomas, MA | 1 |
| Therman, S | 1 |
| Manninen, M | 1 |
| Huttunen, MO | 1 |
| Kaprio, J | 1 |
| Lönnqvist, J | 1 |
| O'Neill, J | 1 |
| Cannon, TD | 1 |
| Tayoshi, S | 1 |
| Sumitani, S | 1 |
| Taniguchi, K | 1 |
| Shibuya-Tayoshi, S | 1 |
| Numata, S | 1 |
| Iga, J | 1 |
| Nakataki, M | 1 |
| Ueno, S | 1 |
| Harada, M | 1 |
| Ohmori, T | 1 |
| Bustillo, JR | 1 |
| Chen, H | 1 |
| Gasparovic, C | 1 |
| Mullins, P | 1 |
| Caprihan, A | 1 |
| Qualls, C | 1 |
| Apfeldorf, W | 1 |
| Lauriello, J | 1 |
| Posse, S | 1 |
| Malherbe, P | 1 |
| Knoflach, F | 1 |
| Hernandez, MC | 1 |
| Hoffmann, T | 1 |
| Schnider, P | 1 |
| Porter, RH | 1 |
| Wettstein, JG | 1 |
| Ballard, TM | 1 |
| Spooren, W | 1 |
| Steward, L | 1 |
| das Neves Duarte, JM | 1 |
| Kulak, A | 1 |
| Gholam-Razaee, MM | 1 |
| Cuenod, M | 1 |
| Gruetter, R | 1 |
| Do, KQ | 1 |
| He, ZL | 1 |
| Deng, W | 1 |
| Li, ML | 1 |
| Chen, ZF | 1 |
| Collier, DA | 1 |
| Ma, X | 1 |
| Li, T | 1 |
| Yamasue, H | 1 |
| Fukui, T | 1 |
| Fukuda, R | 1 |
| Kasai, K | 1 |
| Iwanami, A | 1 |
| Kato, N | 1 |
| Kato, T | 1 |
| Kim, H | 1 |
| McGrath, BM | 1 |
| Silverstone, PH | 1 |
| Yasukawa, R | 1 |
| Miyaoka, T | 1 |
| Mizuno, S | 1 |
| Inagaki, T | 1 |
| Horiguchi, J | 1 |
| Oda, K | 1 |
| Kitagaki, H | 1 |
| Rothermundt, M | 1 |
| Ohrmann, P | 1 |
| Abel, S | 1 |
| Siegmund, A | 1 |
| Pedersen, A | 1 |
| Ponath, G | 1 |
| Suslow, T | 1 |
| Peters, M | 1 |
| Kaestner, F | 1 |
| Heindel, W | 1 |
| Arolt, V | 1 |
| Pfleiderer, B | 1 |
| Wood, SJ | 1 |
| Berger, GE | 1 |
| Wellard, RM | 1 |
| Proffitt, T | 1 |
| McConchie, M | 1 |
| Velakoulis, D | 1 |
| McGorry, PD | 1 |
| Pantelis, C | 1 |
| Levine, J | 3 |
| Goldberger, I | 1 |
| Rapaport, A | 2 |
| Schwartz, M | 1 |
| Schield, C | 1 |
| Elizur, A | 1 |
| Belmaker, RH | 5 |
| Shapiro, J | 3 |
| Agam, G | 4 |
| Kofman, O | 2 |
| Lev, L | 1 |
| Bersudsky, Y | 1 |
| Shimon, H | 1 |
| Sobolev, Y | 1 |
| Davidson, M | 1 |
| Haroutunian, V | 1 |
| Heimberg, C | 1 |
| Komoroski, RA | 1 |
| Lawson, WB | 1 |
| Cardwell, D | 1 |
| Karson, CN | 1 |
| Eluri, R | 1 |
| Paul, C | 1 |
| Roemer, R | 1 |
| Boyko, O | 1 |
| Fukuzako, H | 1 |
| Kodama, S | 1 |
| Fukuzako, T | 1 |
| Yamada, K | 1 |
| Doi, W | 1 |
| Sato, D | 1 |
| Takigawa, M | 1 |
| Biegon, A | 1 |
| Seker, A | 1 |
| Sharma, R | 1 |
| Venkatasubramanian, PN | 1 |
| Bárány, M | 1 |
| Davis, JM | 1 |
| Yao, JK | 1 |
| Yasaei, P | 1 |
| van Kammen, DP | 1 |
| Swahn, CG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Sarcosine on Symptomatology, Quality of Life, Cognitive and Sexual Functioning, Blood Levels of Sarcosine, Glycine, BDNF and MMP-9, Oculomotor, Brain Metabolism and Oxidative Stress Parameters in Schizophrenia.[NCT01503359] | Phase 2 | 70 participants (Anticipated) | Interventional | 2012-01-31 | Completed | ||
| Dietary Supplement N-acetylcysteine (NAC) as a Novel Complementary Medicine to Improve Cognitive Disfunction in Schizophrenia[NCT01885338] | Phase 1 | 26 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Inositol for Comorbid Anxiety in Children and Adolescents With Bipolar Disorder[NCT02811133] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2023-08-31 | Withdrawn (stopped due to Funding terminated) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for inositol and Dementia Praecox
| Article | Year |
|---|---|
A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders--focus on magnetic resonance spectroscopy (MRS) studies.
Topics: Bipolar Disorder; Feeding and Eating Disorders; Humans; Inositol; Magnetic Resonance Spectroscopy; M | 2005 |
Ziskind-Somerfeld Research Award 1993. Biochemical, behavioral, and clinical studies of the role of inositol in lithium treatment and depression.
Topics: Adult; Aged; Animals; Behavior, Animal; Bipolar Disorder; Brain; Clinical Trials as Topic; Depressiv | 1993 |
5 trials available for inositol and Dementia Praecox
| Article | Year |
|---|---|
The trajectory of putative astroglial dysfunction in first episode schizophrenia: a longitudinal 7-Tesla MRS study.
Topics: Adolescent; Adult; Antipsychotic Agents; Astrocytes; Female; Gyrus Cinguli; Humans; Inositol; Longit | 2021 |
Supplementation of antipsychotic treatment with sarcosine – GlyT1 inhibitor – causes changes of glutamatergic (1)NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aspartic Acid; Choline; Creatine; Double-Blind Method; Fema | 2015 |
CSF inositol in schizophrenia and high-dose inositol treatment of schizophrenia.
Topics: Adult; Female; Humans; Inositol; Male; Middle Aged; Psychiatric Status Rating Scales; Schizophrenia | 1994 |
Inositol treatment raises CSF inositol levels.
Topics: Adult; Chronic Disease; Female; Follow-Up Studies; Humans; Inositol; Male; Middle Aged; Schizophreni | 1993 |
Controlled trials of inositol in psychiatry.
Topics: Adult; Alzheimer Disease; Depressive Disorder; Double-Blind Method; Female; Humans; Inositol; Male; | 1997 |
26 other studies available for inositol and Dementia Praecox
| Article | Year |
|---|---|
Evidence for regional hippocampal damage in patients with schizophrenia.
Topics: Adult; Case-Control Studies; Female; Glutamic Acid; Gray Matter; Hippocampus; Humans; Image Interpre | 2018 |
Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.
Topics: Adult; Antipsychotic Agents; Aspartic Acid; Case-Control Studies; Choline; Corpus Striatum; Creatine | 2018 |
Neuro-metabolite profiles of rodent models of psychiatric dysfunctions characterised by MR spectroscopy.
Topics: Anhedonia; Animals; Choline; Depression; Disease Models, Animal; Excitatory Amino Acid Antagonists; | 2019 |
Evaluation of Myo-Inositol as a Potential Biomarker for Depression in Schizophrenia.
Topics: Adult; Case-Control Studies; Depression; Female; Gyrus Cinguli; Humans; Inositol; Magnetic Resonance | 2015 |
Hypo-metabolism of the rostral anterior cingulate cortex associated with working memory impairment in 18 cases of schizophrenia.
Topics: Adult; Aging; Aspartic Acid; Creatine; Female; Gliosis; Gyrus Cinguli; Humans; Inositol; Intelligenc | 2016 |
Alterations in frontal white matter neurochemistry and microstructure in schizophrenia: implications for neuroinflammation.
Topics: Adult; Age Factors; Anisotropy; Aspartic Acid; Case-Control Studies; Choline; Creatine; Diffusion Te | 2015 |
Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction.
Topics: Adult; Aspartic Acid; Choline; Corpus Striatum; Glutamic Acid; Glutamine; Humans; Inositol; Neurogli | 2016 |
Age-related changes in anterior cingulate cortex glutamate in schizophrenia: A (1)H MRS Study at 7 Tesla.
Topics: Adult; Aging; Antipsychotic Agents; Aspartic Acid; Choline; Creatine; Dipeptides; Female; gamma-Amin | 2016 |
Proton MRS in twin pairs discordant for schizophrenia.
Topics: Aspartic Acid; Creatine; Female; Glutamic Acid; Glycerylphosphorylcholine; Hippocampus; Humans; Inos | 2010 |
Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS).
Topics: Adult; Analysis of Variance; Aspartic Acid; Basal Ganglia; Choline; Creatine; Female; Glutamic Acid; | 2009 |
Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla.
Topics: Adult; Age Factors; Aspartic Acid; Biomarkers; Brain; Cognition Disorders; Female; Glutamic Acid; Gl | 2011 |
Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors.
Topics: Action Potentials; Amides; Aminopyridines; Animals; Antipsychotic Agents; Benzeneacetamides; Dose-Re | 2011 |
N-acetylcysteine normalizes neurochemical changes in the glutathione-deficient schizophrenia mouse model during development.
Topics: Acetylcysteine; Alanine; Animals; Aspartic Acid; Cerebral Cortex; Disease Models, Animal; Free Radic | 2012 |
Detection of metabolites in the white matter of frontal lobes and hippocampus with proton in first-episode treatment-naïve schizophrenia patients.
Topics: Adult; Aspartic Acid; Biomarkers; Case-Control Studies; Choline; Creatine; Dominance, Cerebral; Fema | 2012 |
Drug-induced parkinsonism in relation to choline-containing compounds measured by 1H-MR spectroscopy in putamen of chronically medicated patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aspartic Acid; Basal Ganglia Diseases; Choline; Chronic Disease; Creati | 2003 |
Proton magnetic resonance spectroscopy of the anterior cingulate gyrus, insular cortex and thalamus in schizophrenia associated with idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome).
Topics: Adult; Aspartic Acid; Cerebral Cortex; Choline; Female; Gilbert Disease; Gyrus Cinguli; Humans; Inos | 2005 |
Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol.
Topics: Adult; Case-Control Studies; Female; Humans; Immunoassay; Inositol; Magnetic Resonance Spectroscopy; | 2007 |
A 1H-MRS investigation of the medial temporal lobe in antipsychotic-naïve and early-treated first episode psychosis.
Topics: Adult; Antipsychotic Agents; Aspartic Acid; Choline; Creatine; Female; Frontal Lobe; Functional Late | 2008 |
Inositol levels are decreased in postmortem brain of schizophrenic patients.
Topics: Aged; Aged, 80 and over; Brain; Brain Chemistry; Female; Humans; Inositol; Male; Middle Aged; Phosph | 1998 |
Regional proton magnetic resonance spectroscopy in schizophrenia and exploration of drug effect.
Topics: Adult; Aged; Analysis of Variance; Antipsychotic Agents; Aspartic Acid; Basal Ganglia; Brain; Case-C | 1998 |
Single-voxel proton magnetic resonance spectroscopy of the pons and cerebellum in patients with schizophrenia: a preliminary study.
Topics: Adult; Cerebellum; Choline; Creatine; Female; Humans; Inositol; Magnetic Resonance Spectroscopy; Mal | 1998 |
Subtype-associated metabolite differences in the temporal lobe in schizophrenia detected by proton magnetic resonance spectroscopy.
Topics: Aspartic Acid; Brain Mapping; Choline; Creatine; Dominance, Cerebral; Energy Metabolism; Humans; Ino | 1999 |
Scyllo-inositol in post-mortem brain of bipolar, unipolar and schizophrenic patients.
Topics: Adolescent; Adult; Aged; Animals; Antipsychotic Agents; Bipolar Disorder; Brain; Depressive Disorder | 2000 |
Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients.
Topics: Adult; Aspartic Acid; Basal Ganglia; Bipolar Disorder; Choline; Creatine; Depressive Disorder; Energ | 1992 |
Increased turnover of platelet phosphatidylinositol in schizophrenia.
Topics: Adult; Antipsychotic Agents; Blood Platelets; Haloperidol; Humans; Hydrolysis; Inositol; Male; Middl | 1992 |
Gas chromatographic-mass spectrometric determination of myo-inositol in human cerebrospinal fluid.
Topics: Adult; Arthritis, Rheumatoid; Chlorpromazine; Female; Gas Chromatography-Mass Spectrometry; Humans; | 1985 |